Dizal Pharmaceutical: Multiple latest research results in the field of lung cancer announced at the 2025 World Conference on Lung Cancer (WCLC)
I'm PortAI, I can summarize articles.
Dizal Pharmaceutical announced 11 latest studies on its novel lung cancer targeted drug Shuwozhe® and highly selective JAK1 inhibitor Gaoruizhe® in the field of non-small cell lung cancer at the 2025 World Conference on Lung Cancer (WCLC). The international multicenter registration clinical study "Wukong 1B" of Shuwozhe® demonstrated a favorable benefit/risk ratio in the treatment of NSCLC with EGFR exon 20 insertion mutations. The research on Gaoruizhe® showed that its combination with anti-PD-1 monoclonal antibody treatment for advanced NSCLC is controllable in terms of safety
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments